Inveready
VC Fund
Barcelona, Spain
Inveready is a Southern Europe leading alternative investor with +2bn€ of assets under management, investing across 35+ funds in Venture Capital, BioTech, Venture Debt, Private Equity, Public Equity, Infrastructure, Fund of Funds, and other. Founded in 2008, Inveready counts on 250+ active companies and 64 exits.Some of our portfolio companieshave been acquired by multinationals such as Intel, Symantec, IBM, and Facebook, whilst others are listed in public markets such as NASDAQ, the Spanish BME Growth, AIM London, and Euronext Growth. (visit www.inveready.com for more information).
- Total investments:
- 280
- Last investment:
- Lead investor:
- 43%
- Fund size:
- $63M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Inveready invests in
Stages Inveready invests in
Countries Inveready invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Round size
- Seed
- $400k–$4.7M
- Debt Financing
- $1.2M–$6.5M
- Venture - Series Unknown
- $594k–$5.7M
Investment Focus
Industry
- Software 53 (19%)
- Biotechnology 34 (12%)
- Health Care 31 (11%)
- Information Technology 29 (10%)
- Medical 17 (6%)
Stage
- Seed 68 (24%)
- Venture - Series Unknown 55 (20%)
- Debt Financing 30 (11%)
- Series A 24 (9%)
- Funding Round 14 (5%)
Country
- Spain 170 (61%)
- United States 9 (3%)
- France 5 (2%)
- United Kingdom 5 (2%)
- Canada 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ignacio Fonts
Member BOD
|
Member BOD | Total investments: 37 | Find email | |
Sara Secall
Partner& Life Sciences Investment Director
|
Partner& Life Sciences Investment Director | Total investments: 9 | Find email | |
|
Adanne Branch
Owner
|
Owner | Total investments: 0 | Find email | |
Aniol Brosa
Partner
|
Partner | Total investments: 6 | Find email | |
Carlos Conti
GP
|
GP | Total investments: 6 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mirai offers solutions for balance sheet management, financial risk, and regulatory compliance. | $5.7M / Debt Financing / Sep 22, 2026 | ||
| Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of the central nervous system. It focuses on the development of a first-in-class drug for the treatment of fragile X syndrome. | $4.2M / Venture - Series Unknown / Sep 10, 2026 | ||
| Inventia Kinetics specializes in the design, analysis, and manufacture of equipment and assembly tools for electronics sector. | $5.7M / Debt Financing / Jul 16, 2026 | ||
Telum Therapeutics
|
Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M / Series A / Jul 01, 2026 | |
| Dolfin is a software company that provides automated sales compensation solutions for businesses. | $2.5M / Seed / May 07, 2026 | ||
| Iteria Biopharma focused on discovering and developing precision oncology drugs, particularly first-in-class new chemical entities (NCEs) for challenging cancer targets with high unmet medical needs. | $5.9M / Seed / Apr 16, 2026 | ||
| 53Biologics is a company that are into manufacturing of bio technology and bio development products. They offer plasmid DNA production services to meet demand and hasten the development of innovative medicines. Their goal is to become an excellent CDMO with each success and disappointment. | Venture - Series Unknown / Mar 25, 2026 | ||
| Pharmacelera is a company that applies accurate Quantum-Mechanics (QM) algorithms, Machine Learning (ML) and High-Performance Computing (HPC) to mine an unexploited chemical space and propose molecular candidates that have higher chances to become a drug. The patented computational technology derives from more than 25 years of research at theUniversity of Barcelona and it has been validated in scientific peer-reviewed publications and benchmarking studies performed by our users and customers. | $7.1M / Venture - Series Unknown / Feb 18, 2026 | ||
| Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of the central nervous system. It focuses on the development of a first-in-class drug for the treatment of fragile X syndrome. | $1.9M / Venture - Series Unknown / Jan 31, 2026 | ||
| Experience Group is a global strategic platform that focuses on brands. Through license partnerships with multinational corporations, the company owns and runs retail and wholesale businesses, assisting them in increasing their market presence, enhancing customer engagement, and fostering growth across various sales platforms. | $5.8M / Debt Financing / Nov 10, 2025 | ||
| See all 280 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Inveready invest in?
Inveready invests primarily in Software, Biotechnology and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 280 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Inveready's check size?
Inveready typically joins rounds of $400k–$4.7M at Seed, $1.2M–$6.5M at Debt Financing and $594k–$5.7M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Inveready participates in.
How do I contact Inveready?
Public channels for Inveready include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Inveready?
The team at Inveready includes Ignacio Fonts (Member BOD), Sara Secall (Partner& Life Sciences Investment Director) and Adanne Branch (Owner), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
